학술논문
Dabigatran etexilate in a vitamin-K antagonist non responder patient during Heartware HVAD support.
Document Type
Academic Journal
Author
Baronetto A; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Centofanti P; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Attisani M; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Boffini M; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Ricci D; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Simonato E; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.; Rinaldi M; Division of Cardiac Surgery, San Giovanni Battista Hospital 'Molinette', University of Turin, Turin, Italy.
Source
Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8908809 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1540-8191 (Electronic) Linking ISSN: 08860440 NLM ISO Abbreviation: J Card Surg Subsets: MEDLINE
Subject
Language
English
Abstract
We report a case of a patient supported with a HeartWare left ventricular assist device for idiopathic cardiomyopathy who was resistance to vitamin-K antagonists three months after implantation. The patient initially started low-molecular-weight heparin therapy and then, after the onset of an ischemic stroke, switched to dabigatran etexilate (DE). The patient had progressive recovery of cardiac function for which the device was explanted. No thrombotic or bleeding events occurred during DE therapy.
(© 2017 Wiley Periodicals, Inc.)
(© 2017 Wiley Periodicals, Inc.)